3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Ascletis Pharma's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -141.23%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Ascletis Pharma's 3-Year ROIIC % or its related term are showing as below:
ASCLF's 3-Year ROIIC % is ranked worse than 75.57% of 1322
companies
in the Biotechnology industry
Industry Median: -4.82
vs ASCLF: -141.23
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Ascletis Pharma 3-Year ROIIC % Related Terms
Ascletis Pharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Ascletis Pharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASCLF vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Ascletis Pharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascletis Pharma 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascletis Pharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Ascletis Pharma's 3-Year ROIIC % falls into.
Ascletis Pharma's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -63.394 (Dec. 2025) - -48.715 (Dec. 2022) )
/
( 31.759 (Dec. 2025) - 21.372 (Dec. 2022) )
=
-14.679
/
10.387
=
-141.32%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Ascletis Pharma (ASCLF) has a 3-Year ROIIC % of -141.23 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Ascletis Pharma and its competitors. According to the industry distribution chart, Ascletis Pharma ranks #999 out of 1322 companies in the Biotechnology industry, placing it in the top 75.6%.
Is Ascletis Pharma's 3-Year ROIIC % too high?
Ascletis Pharma's current 3-Year ROIIC % is -141.23. Based on the distribution chart, Ascletis Pharma ranks #999 out of 1322 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascletis Pharma has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ascletis Pharma's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascletis Pharma ranks #999 out of 1322 companies for 3-Year ROIIC %. This places Ascletis Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Ascletis Pharma and its competitors. Ascletis Pharma's current 3-Year ROIIC % is -141.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascletis Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ascletis Pharma (ASCLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $1.44 — trading 7100% above its estimated fair value. The current 3-Year ROIIC % is -141.23. Ascletis Pharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Ascletis Pharma (ASCLF), the current 3-Year ROIIC % is -141.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascletis Pharma (ASCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued.
The current stock price of $1.44 is trading 7100% above its estimated GF Value™ of $0.02.
GuruFocus considers Ascletis Pharma to be Significantly Overvalued.
Key valuation signals for ASCLF:
3-Year ROIIC %: -141.23
GF Value™: $0.02 vs. price of $1.44 (7100% above fair value)
No single metric tells the full story. See the ASCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
38GF Score
Get the complete analysis for ASCLF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASCLF has been successfully added to your 
